197 related articles for article (PubMed ID: 23046238)
21. The Saudi experience in fludarabine-based conditioning regimens in patients with Fanconi anemia undergoing stem cell transplantation: excellent outcome in recipients of matched related stem cells but not in recipients of unrelated cord blood stem cells.
Ayas M; Al-Seraihi A; El-Solh H; Al-Ahmari A; Khairy A; Aldali A; Markiz S; Siddiqui K; Al-Jefri A
Biol Blood Marrow Transplant; 2012 Apr; 18(4):627-32. PubMed ID: 21871862
[TBL] [Abstract][Full Text] [Related]
22. Hematopoietic stem cell transplantation in thalassemia.
Gaziev J; Sodani P; Lucarelli G
Bone Marrow Transplant; 2008 Aug; 42 Suppl 1():S41. PubMed ID: 18724298
[TBL] [Abstract][Full Text] [Related]
23. Comparison between an artificial neural network and logistic regression in predicting acute graft-vs-host disease after unrelated donor hematopoietic stem cell transplantation in thalassemia patients.
Caocci G; Baccoli R; Vacca A; Mastronuzzi A; Bertaina A; Piras E; Littera R; Locatelli F; Carcassi C; La Nasa G
Exp Hematol; 2010 May; 38(5):426-33. PubMed ID: 20206661
[TBL] [Abstract][Full Text] [Related]
24. Management of thalassemia major (Cooley's anemia).
Piomelli S; Loew T
Hematol Oncol Clin North Am; 1991 Jun; 5(3):557-69. PubMed ID: 1864823
[TBL] [Abstract][Full Text] [Related]
25. The second mini-transplant for unstable mixed chimerism within the first 100 days after hematopoietic stem cell transplant in severe thalassemia.
Choeyprasert W; Pakakasama S; Anurathapan U; Songdej D; Sirachainun N; Sirireung S; Panthangkool W; Hongeng S
Pediatr Transplant; 2012 Sep; 16(6):E238-40. PubMed ID: 21895905
[TBL] [Abstract][Full Text] [Related]
26. Gene therapy for homozygous beta-thalassemia. Is it a reality?
Boulad F; Rivière I; Sadelain M
Hemoglobin; 2009; 33 Suppl 1():S188-96. PubMed ID: 20001625
[TBL] [Abstract][Full Text] [Related]
27. Allogeneic stem cell transplantation with fludarabine-based, less intensive conditioning regimens as adoptive immunotherapy in advanced Hodgkin's disease.
Anderlini P; Giralt S; Andersson B; Ueno NT; Khouri I; Acholonu S; Cohen A; Körbling MJ; Manning J; Romaguera J; Sarris A; Rodriguez ; Hagemeister F; Mclaughlin P; Cabanillas F; Champlin RE
Bone Marrow Transplant; 2000 Sep; 26(6):615-20. PubMed ID: 11041566
[TBL] [Abstract][Full Text] [Related]
28. Effect of serum panel reactive antibodies on allogeneic hematopoietic stem cell transplantation in pediatric thalassemia patients: A single-center experience.
Malbora B; Sarbay H; Dogusan Z; Atay AA
Pediatr Transplant; 2024 Feb; 28(1):e14648. PubMed ID: 38063291
[TBL] [Abstract][Full Text] [Related]
29. Results of an outpatient-based stem cell allotransplant program using nonmyeloablative conditioning regimens.
Ruiz-Argüelles GJ; Gómez-Almaguer D; Ruiz-Argüelles A; González-Llano O; Cantú OG; Jaime-Pérez JC
Am J Hematol; 2001 Apr; 66(4):241-4. PubMed ID: 11279633
[TBL] [Abstract][Full Text] [Related]
30. Unrelated bone marrow transplantation for beta-thalassemia patients: The experience of the Italian Bone Marrow Transplant Group.
La Nasa G; Argiolu F; Giardini C; Pession A; Fagioli F; Caocci G; Vacca A; De Stefano P; Piras E; Ledda A; Piroddi A; Littera R; Nesci S; Locatelli F
Ann N Y Acad Sci; 2005; 1054():186-95. PubMed ID: 16339665
[TBL] [Abstract][Full Text] [Related]
31. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
32. Red blood cell transfusion therapy and iron chelation in patients with myelodysplastic syndromes.
Malcovati L
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S305-11. PubMed ID: 19778858
[TBL] [Abstract][Full Text] [Related]
33. Hematopoietic stem cell transplantation for children with thalassemia major in China.
Fang JP; Xu LH
Pediatr Blood Cancer; 2010 Dec; 55(6):1062-5. PubMed ID: 20979169
[TBL] [Abstract][Full Text] [Related]
34. Impact of pretransplant splenectomy on patients with beta-thalassemia major undergoing a matched-related allogeneic stem cell transplantation.
Mathews V; George B; Lakshmi KM; Viswabandya A; John JM; Sitaram U; Daniel D; Chandy M; Srivastava A
Pediatr Transplant; 2009 Mar; 13(2):171-6. PubMed ID: 18482210
[TBL] [Abstract][Full Text] [Related]
35. Hematopoietic Stem Cell Transplantation in Patients with Hemoglobinopathies.
Yesilipek MA
Hemoglobin; 2020 Nov; 44(6):377-384. PubMed ID: 33050763
[TBL] [Abstract][Full Text] [Related]
36. The value of donor lymphocyte infusions in thalassemia patients at imminent risk of graft rejection following stem cell transplantation.
Karasu GT; Yesilipek MA; Karauzum SB; Uygun V; Manguoglu E; Kupesiz A; Hazar V
Pediatr Blood Cancer; 2012 Mar; 58(3):453-8. PubMed ID: 21990066
[TBL] [Abstract][Full Text] [Related]
37. Thalassemia Major: Transplantation or Transfusion and Chelation.
Mohamed SY
Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):290-298. PubMed ID: 28651066
[TBL] [Abstract][Full Text] [Related]
38. Is the Benefit-Risk Ratio for Patients with Transfusion-Dependent Thalassemia Treated by Unrelated Cord Blood Transplantation Favorable?
Jaing TH
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29156642
[TBL] [Abstract][Full Text] [Related]
39. Optimizing management of myelodysplastic syndromes post-allogeneic transplantation.
Sockel K; Ehninger G; Hofbauer LC; Platzbecker U
Expert Rev Hematol; 2011 Dec; 4(6):669-80. PubMed ID: 22077530
[TBL] [Abstract][Full Text] [Related]
40. Unrelated bone marrow transplantation for beta-thalassemia major: report of the first 2 successful cases in Asia.
Zhu WG; Feng ZC; Li QP; Zhong CX; Li ZD; Lu ZG
Di Yi Jun Yi Da Xue Xue Bao; 2003 Mar; 23(3):281-2. PubMed ID: 12651255
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
